BR112022001678A2 - Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes - Google Patents
Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partesInfo
- Publication number
- BR112022001678A2 BR112022001678A2 BR112022001678A BR112022001678A BR112022001678A2 BR 112022001678 A2 BR112022001678 A2 BR 112022001678A2 BR 112022001678 A BR112022001678 A BR 112022001678A BR 112022001678 A BR112022001678 A BR 112022001678A BR 112022001678 A2 BR112022001678 A2 BR 112022001678A2
- Authority
- BR
- Brazil
- Prior art keywords
- mek inhibitor
- stroke
- kit
- developing
- risk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes. a presente invenção se refere a um inibidor mek e composições do mesmo, para o uso no tratamento de acidente vascular cerebral, em particular, tratamento da hemorragia subaracnoidea (sah).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19189069 | 2019-07-30 | ||
PCT/EP2020/071209 WO2021018866A1 (en) | 2019-07-30 | 2020-07-28 | Mek inhibitor for treatment of stroke |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022001678A2 true BR112022001678A2 (pt) | 2022-05-03 |
Family
ID=67513366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022001678A BR112022001678A2 (pt) | 2019-07-30 | 2020-07-28 | Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220273660A1 (pt) |
EP (1) | EP4003356A1 (pt) |
JP (1) | JP2022542514A (pt) |
KR (1) | KR20220106106A (pt) |
CN (1) | CN114502169A (pt) |
AU (1) | AU2020323687A1 (pt) |
BR (1) | BR112022001678A2 (pt) |
CA (1) | CA3146052A1 (pt) |
IL (1) | IL290033A (pt) |
MX (1) | MX2022001328A (pt) |
WO (1) | WO2021018866A1 (pt) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2834236B1 (en) * | 2012-03-14 | 2019-05-22 | Lupin Limited | Heterocyclyl compounds |
WO2016009306A1 (en) * | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
-
2020
- 2020-07-28 WO PCT/EP2020/071209 patent/WO2021018866A1/en unknown
- 2020-07-28 MX MX2022001328A patent/MX2022001328A/es unknown
- 2020-07-28 EP EP20744048.8A patent/EP4003356A1/en active Pending
- 2020-07-28 CN CN202080068488.5A patent/CN114502169A/zh active Pending
- 2020-07-28 KR KR1020227005988A patent/KR20220106106A/ko unknown
- 2020-07-28 BR BR112022001678A patent/BR112022001678A2/pt unknown
- 2020-07-28 JP JP2022506074A patent/JP2022542514A/ja active Pending
- 2020-07-28 AU AU2020323687A patent/AU2020323687A1/en active Pending
- 2020-07-28 US US17/630,287 patent/US20220273660A1/en active Pending
- 2020-07-28 CA CA3146052A patent/CA3146052A1/en active Pending
-
2022
- 2022-01-23 IL IL290033A patent/IL290033A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220273660A1 (en) | 2022-09-01 |
JP2022542514A (ja) | 2022-10-04 |
CN114502169A (zh) | 2022-05-13 |
EP4003356A1 (en) | 2022-06-01 |
KR20220106106A (ko) | 2022-07-28 |
WO2021018866A1 (en) | 2021-02-04 |
IL290033A (en) | 2022-03-01 |
MX2022001328A (es) | 2022-05-20 |
CA3146052A1 (en) | 2021-02-04 |
AU2020323687A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021006392A2 (pt) | moduladores da alfa-1 antitripsina | |
BR112022011421A2 (pt) | Inibidores da proteína mutante kras | |
BR112019000598A2 (pt) | rna para terapia de câncer | |
CO2021015264A2 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
BR112019016497A2 (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer. | |
BR112017016766A2 (pt) | composições farmacêuticas para terapia de combinação | |
BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
BR112018069976A2 (pt) | anticorpo multiespecífico isolado ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, kit, e, método para tratamento de um indivíduo. | |
CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
BR112016026560A2 (pt) | Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção | |
CO2022003582A2 (es) | Métodos para el tratamiento de la oftalmopatía tiroidea | |
BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
BR112022001341A2 (pt) | Inibidores de enzima | |
BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
BR112021012056A2 (pt) | Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
BR112022023013A2 (pt) | Inibidores de mek para tratamento ou prevenção de infecções por coronavírus e/ou de tempestade de citocinas de covid-19 | |
ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
BR112019022912A2 (pt) | Métodos e composições para tratar doenças oculares alérgicas | |
CL2022001357A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
BR112019008241A2 (pt) | tratamento do prurigo nodular | |
BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase |